ISDA

Deposition Date 2009-11-10

Release Date 2010-02-23

Last Version Date 2024-05-08

Entry Detail

PDB ID:

2WXV

Keywords:

TRANSFERASE

Title:

Structure of CDK2-CYCLIN A with a Pyrazolo(4,3-h) quinazoline-3- carboxamide inhibitor

Biological Source:

Source Organism:

HOMO SAPIENS (Taxon ID: 9606)

Host Organism:

TRICHOPLUSIA NI

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.60 Å

R-Value Free:

0.24

R-Value Work:

0.21

R-Value Observed:

0.21

Space Group:

P 62 2 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:CELL DIVISION PROTEIN KINASE 2
Gene (Uniprot):CDK2
Chain IDs:A, C
Chain Length:309
Number of Molecules:2
Biological Source:HOMO SAPIENS

UniProt ID:P24941 Pfam ID:PF00069 EC:2.7.11.22

Protein Blast

Polymer Type:polypeptide(L)
Molecule:CYCLIN-A2
Gene (Uniprot):CCNA2
Chain IDs:B, D
Chain Length:265
Number of Molecules:2
Biological Source:HOMO SAPIENS

UniProt ID:P20248 Pfam ID:PF00134, PF02984

Ligand Molecules

SO4

WXV

Primary Citation

Identification of Potent Pyrazolo[4,3-H]Quinazoline-3-Carboxamides as Multi-Cyclin-Dependent Kinase Inhibitors.

Traquandi, G, Ciomei, M, Ballinari, D, Casale, E, Colombo, N, Croci, V, Fiorentini, F, Isacchi, A, Longo, A, Mercurio, C, Panzeri, A, Pastori, W, Pevarello, P, Volpi, D, Roussel, P, Vulpetti, A, Brasca, M.G.Show

J.Med.Chem. 53 2171 ? (2010)

PMID: 20141146 DOI: 10.1021/JM901710H

Abstact

Abnormal proliferation mediated by disruption of the mechanisms that keep the cell cycle under control is a hallmark of virtually all cancer cells. Compounds targeting complexes between cyclin-dependent kinases (CDKs) and cyclins (Cy) and inhibiting their activity are regarded as promising antitumor agents to complement the existing therapies. An expansion of pyrazolo[4,3-h]quinazoline chemical class oriented to the development of three points of variability was undertaken leading to a series of compounds able to inhibit CDKs both in vitro and in vivo. Starting from the CDK selective but poorly soluble hit compound 1, we succeeded in obtaining several compounds showing enhanced inhibitory activity both on CDKs and on tumor cells and displaying improved physical properties and pharmacokinetic behavior. Our study led to the identification of compound 59 as a highly potent, orally bioavailable CDK inhibitor that exhibited significant in vivo efficacy on the A2780 ovarian carcinoma xenograft model. The demonstrated mechanisms of action of compound 59 on cancer cell lines and its ability to inhibit tumor growth in vivo render this compound very interesting as potential antineoplastic agent.

Legend

Protein

Chemical

Disease

Primary Citation of related structures